Imaging test for tumors using a new tracer agent
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and expected to live at least 12 weeks.
- You cannot have had chemotherapy or radiation in the past.
- You must have at least one tumor that can be measured by standard imaging.
- You must be able to lie still for 30 minutes.
- Women who are pregnant, breastfeeding, or planning pregnancy cannot join. Others must use birth control during the study.
- You must agree to follow all study visits and provide written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if a new imaging agent can find hard-to-treat pituitary tumors that have come back after surgery. It may help doctors decide the best way to manage these tumors.
This trial tests a new imaging method that uses a special dye to highlight a protein called Trop-2 found on some brain tumor cells. The goal is to see if this dye can help doctors see the tumor more clearly before surgery, which may improve surgical planning.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
Hear when a new Malignant Neoplasms of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.